SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Acasti Pharma Inc. – ‘20-F’ for 3/31/18 – ‘ZIP’

On:  Friday, 6/29/18, at 11:35am ET   ·   For:  3/31/18   ·   Accession #:  1171843-18-4911   ·   File #:  1-35776

Previous ‘20-F’:  ‘20-F’ on 6/27/17 for 3/31/17   ·   Next & Latest:  ‘20-F’ on 6/26/19 for 3/31/19   ·   15 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/29/18  Acasti Pharma Inc.                20-F        3/31/18  110:35M                                    Globenewswire Inc./FA

Annual Report by a Foreign Non-Canadian Issuer   —   Form 20-F   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report by a Foreign Non-Canadian Issuer      HTML   1.24M 
 2: EX-2.4      Plan of Acquisition, Reorganization, Arrangement,   HTML     44K 
                Liquidation or Succession                                        
 3: EX-2.5      Plan of Acquisition, Reorganization, Arrangement,   HTML     58K 
                Liquidation or Succession                                        
 6: EX-13.1     Annual or Quarterly Report to Security Holders      HTML     31K 
 7: EX-13.2     Annual or Quarterly Report to Security Holders      HTML     31K 
 4: EX-12.1     Statement re: Computation of Ratios                 HTML     35K 
 5: EX-12.2     Statement re: Computation of Ratios                 HTML     36K 
 8: EX-15.1     Letter re: Unaudited Interim Financial Info         HTML     34K 
15: R1          Document And Entity Information                     HTML     57K 
16: R2          Statements of Financial Position (February 2017     HTML     93K 
                Unaudited)                                                       
17: R3          Statements of Earnings and Comprehensive Loss       HTML     60K 
                (Twelve Month and Month Ended 2017 Unaudited)                    
18: R4          Statements of Changes in Equity (Twelve Month and   HTML    108K 
                Month Ended 2017 Unaudited)                                      
19: R5          Statements of Changes in Equity (Twelve Month and   HTML     34K 
                Month Ended 2017 Unaudited) (Parentheticals)                     
20: R6          Statements of Cash Flows (Twelve Month and Month    HTML    111K 
                Ended 2017 Unaudited)                                            
21: R7          Note 1 - Reporting Entity                           HTML     39K 
22: R8          Note 2 - Basis of Preparation                       HTML     52K 
23: R9          Note 3 - Significant Accounting Policies            HTML     95K 
24: R10         Note 4 - Receivables                                HTML     43K 
25: R11         Note 5 - Other Assets                               HTML     34K 
26: R12         Note 6 - Related Parties                            HTML     84K 
27: R13         Note 7 - Government Assistance                      HTML     53K 
28: R14         Note 8 - Equipment                                  HTML     90K 
29: R15         Note 9 - Intangible Assets                          HTML     65K 
30: R16         Note 10 - Trade and Other Payables                  HTML     44K 
31: R17         Note 11 - Derivative Warrant Liabilities            HTML     88K 
32: R18         Note 12 - Unsecured Convertible Debentures          HTML     64K 
33: R19         Note 13 - Capital and Other Components of Equity    HTML    140K 
34: R20         Note 14 - Personnel Expenses                        HTML     47K 
35: R21         Note 15 - Financial Expenses                        HTML     69K 
36: R22         Note 16 - Share-based Payments                      HTML    120K 
37: R23         Note 17 - Loss Per Share                            HTML     33K 
38: R24         Note 18 - Supplemental Cash Flow Disclosure         HTML     75K 
39: R25         Note 19 - Income Taxes                              HTML    107K 
40: R26         Note 20 - Financial Instruments                     HTML    124K 
41: R27         Note 21 - Commitments and Contingencies             HTML     39K 
42: R28         Note 22 - Determination of Fair Values              HTML     39K 
43: R29         Note 23 - Capital Management                        HTML     49K 
44: R30         Note 24 - Subsequent Event                          HTML     39K 
45: R31         Significant Accounting Policies (Policies)          HTML    132K 
46: R32         Note 3 - Significant Accounting Policies (Tables)   HTML     38K 
47: R33         Note 4 - Receivables (Tables)                       HTML     42K 
48: R34         Note 6 - Related Parties (Tables)                   HTML     75K 
49: R35         Note 7 - Government Assistance (Tables)             HTML     53K 
50: R36         Note 8 - Equipment (Tables)                         HTML     88K 
51: R37         Note 9 - Intangible Assets (Tables)                 HTML     63K 
52: R38         Note 10 - Trade and Other Payables (Tables)         HTML     43K 
53: R39         Note 11 - Derivative Warrant Liabilities (Tables)   HTML     87K 
54: R40         Note 12 - Unsecured Convertible Debentures          HTML     57K 
                (Tables)                                                         
55: R41         Note 13 - Capital and Other Components of Equity    HTML    114K 
                (Tables)                                                         
56: R42         Note 14 - Personnel Expenses (Tables)               HTML     47K 
57: R43         Note 15 - Financial Expenses (Tables)               HTML     68K 
58: R44         Note 16 - Share-based Payments (Tables)             HTML    107K 
59: R45         Note 18 - Supplemental Cash Flow Disclosure         HTML     75K 
                (Tables)                                                         
60: R46         Note 19 - Income Taxes (Tables)                     HTML    108K 
61: R47         Note 20 - Financial Instruments (Tables)            HTML    119K 
62: R48         Note 23 - Capital Management (Tables)               HTML     40K 
63: R49         Note 1 - Reporting Entity (Details Textual)         HTML     36K 
64: R50         Note 2 - Basis of Preparation (Details Textual)     HTML     46K 
65: R51         Note 3 - Significant Accounting Policies (Details   HTML     37K 
                Textual)                                                         
66: R52         Note 3 - Significant Accounting Policies -          HTML     50K 
                Estimated Useful Lives and Rates (Details)                       
67: R53         Note 4 - Receivables - Schedule of Receivables      HTML     40K 
                (Details)                                                        
68: R54         Note 5 - Other Assets (Details Textual)             HTML     44K 
69: R55         Note 6 - Related Parties (Details Textual)          HTML     58K 
70: R56         Note 6 - Related Parties - Administrative and       HTML     47K 
                Research and Development Expenses (Details)                      
71: R57         Note 6 - Related Parties - Key Management           HTML     41K 
                Personnel Compensation (Details)                                 
72: R58         Note 7 - Government Assistance - Government Grants  HTML     37K 
                and Investment Tax Credits (Details)                             
73: R59         Note 7 - Government Assistance - Unrecognized       HTML     54K 
                Federal Tax Credits (Details)                                    
74: R60         Note 8 - Equipment (Details Textual)                HTML     34K 
75: R61         Note 8 - Equipment - Components of Equipment        HTML     77K 
                (Details)                                                        
76: R62         Note 9 - Intangible Assets - Components of          HTML     66K 
                Intangible Assets (Details)                                      
77: R63         Note 10 - Trade and Other Payables - Components of  HTML     43K 
                Trade and Other Payables (Details)                               
78: R64         Note 11 - Derivative Warrant Liabilities (Details   HTML     39K 
                Textual)                                                         
79: R65         Note 11 - Derivative Warrant Liabilities -          HTML     46K 
                Reconciliation (Details)                                         
80: R66         Note 11 - Derivative Warrant Liabilities -          HTML     53K 
                Assumptions (Details)                                            
81: R67         Note 12 - Unsecured Convertible Debentures          HTML     56K 
                (Details Textual)                                                
82: R68         Note 12 - Unsecured Convertible Debentures -        HTML     56K 
                Liability and Equity Component Portions (Details)                
83: R69         Note 13 - Capital and Other Components of Equity    HTML    198K 
                (Details Textual)                                                
84: R70         Note 13 - Capital and Other Components of Equity -  HTML     47K 
                Assumptions (Details)                                            
85: R71         Note 13 - Capital and Other Components of Equity -  HTML     36K 
                Unsecured Convertible Debentures (Details)                       
86: R72         Note 13 - Capital and Other Components of Equity -  HTML     67K 
                Warrants Outstanding (Details)                                   
87: R73         Note 14 - Personnel Expenses - Components of        HTML     42K 
                Personnel Expenses (Details)                                     
88: R74         Note 15 - Financial Expenses - Components of        HTML     60K 
                Finance Income (Expenses) (Details)                              
89: R75         Note 16 - Share-based Payments (Details Textual)    HTML     74K 
90: R76         Note 16 - Share-based Payments - Option Activity    HTML     63K 
                (Details)                                                        
91: R77         Note 16 - Share-based Payments - Weighted Average   HTML     46K 
                Assumptions (Details)                                            
92: R78         Note 16 - Share-based Payments - Outstanding and    HTML     81K 
                Exercisable Options (Details)                                    
93: R79         Note 18 - Supplemental Cash Flow Disclosure -       HTML     48K 
                Changes in Non-cash Operating Items (Details)                    
94: R80         Note 18 - Supplemental Cash Flow Disclosure -       HTML     50K 
                Non-cash Transactions (Details)                                  
95: R81         Note 19 - Income Taxes (Details Textual)            HTML     33K 
96: R82         Note 19 - Income Taxes - Deferred Tax (Recovery)    HTML     42K 
                Expense (Details)                                                
97: R83         Note 19 - Income Taxes - Reconciliation of          HTML     56K 
                Effective Tax Rate (Details)                                     
98: R84         Note 19 - Income Taxes - Unrecognized Deferred Tax  HTML     52K 
                Assets (Details)                                                 
99: R85         Note 19 - Income Taxes - Tax attributes and         HTML     72K 
                Temporary Differences Available to Reduce Future                 
                Years' Taxable Income (Details)                                  
100: R86         Note 20 - Financial Instruments - Currency Risk     HTML     61K  
                (Details)                                                        
101: R87         Note 20 - Financial Instruments - Interest Rate     HTML     37K  
                Risk (Details)                                                   
102: R88         Note 20 - Financial Instruments - Financial         HTML     54K  
                Liabilities (Details)                                            
103: R89         Note 21 - Commitments and Contingencies (Details    HTML     48K  
                Textual)                                                         
104: R90         Note 22 - Determination of Fair Values (Details     HTML     36K  
                Textual)                                                         
105: R91         Note 23 - Capital Management (Details Textual)      HTML     60K  
106: R92         Note 23 - Capital Management - Cash and Cash        HTML     38K  
                Equivalents (Details)                                            
107: R93         Note 24 - Subsequent Event (Details Textual)        HTML     77K  
109: XML         IDEA XML File -- Filing Summary                      XML    199K  
108: EXCEL       IDEA Workbook of Financial Reports                  XLSX    110K  
 9: EX-101.INS  XBRL Instance -- acst-20180331                       XML   3.75M 
11: EX-101.CAL  XBRL Calculations -- acst-20180331_cal               XML    155K 
12: EX-101.DEF  XBRL Definitions -- acst-20180331_def                XML   1.53M 
13: EX-101.LAB  XBRL Labels -- acst-20180331_lab                     XML   1.19M 
14: EX-101.PRE  XBRL Presentations -- acst-20180331_pre              XML   1.55M 
10: EX-101.SCH  XBRL Schema -- acst-20180331                         XSD    322K 
110: ZIP         XBRL Zipped Folder -- 0001171843-18-004911-xbrl      Zip    227K  


‘ZIP’   —   XBRL Zipped Folder — 0001171843-18-004911-xbrl


This is an XBRL Zipped Folder.

        Download this zipped .zip folder
 
Files:acst-20180331.xml
acst-20180331.xsd
acst-20180331_cal.xml
acst-20180331_def.xml
acst-20180331_lab.xml
acst-20180331_pre.xml


15 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/23/23  Acasti Pharma Inc.                10-K        3/31/23  105:16M                                    Donnelley … Solutions/FA
 2/14/23  Acasti Pharma Inc.                10-Q       12/31/22   57:9.5M                                   Donnelley … Solutions/FA
11/14/22  Acasti Pharma Inc.                10-Q        9/30/22   57:9.2M                                   Donnelley … Solutions/FA
 8/11/22  Acasti Pharma Inc.                10-Q        6/30/22   57:7.7M                                   Donnelley … Solutions/FA
 7/29/22  Acasti Pharma Inc.                10-K/A      3/31/22   14:1.2M                                   Donnelley … Solutions/FA
 6/21/22  Acasti Pharma Inc.                10-K        3/31/22   96:14M                                    Donnelley … Solutions/FA
 2/14/22  Acasti Pharma Inc.                10-Q       12/31/21   66:10M                                    Donnelley … Solutions/FA
11/10/21  Acasti Pharma Inc.                10-Q        9/30/21   65:6.7M                                   Globenewswire Inc./FA
 8/12/21  Acasti Pharma Inc.                10-Q        6/30/21   57:4M                                     Globenewswire Inc./FA
 7/13/21  Acasti Pharma Inc.                S-4/A                  5:5.6M                                   Donnelley … Solutions/FA
 7/01/21  Acasti Pharma Inc.                S-4                   17:6.6M                                   Donnelley … Solutions/FA
 6/22/21  Acasti Pharma Inc.                10-K        3/31/21   92:6.3M                                   Globenewswire Inc./FA
 2/09/21  Acasti Pharma Inc.                10-Q       12/31/20   64:3.8M                                   Globenewswire Inc./FA
11/16/20  Acasti Pharma Inc.                10-Q        9/30/20   58:3.4M                                   Globenewswire Inc./FA
 8/13/20  Acasti Pharma Inc.                10-Q        6/30/20   54:2.7M                                   Globenewswire Inc./FA
Top
Filing Submission 0001171843-18-004911   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 17, 5:09:50.2pm ET